Stay updated with breaking news from Available Effectiveness Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the...
/PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the...
SILVER SPRING, Md., July 13, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the...
Share this article Share this article SILVER SPRING, Md., May 10, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. The FDA amended the EUA originally issued on Dec. 11, 2020 for administration in individuals 16 years of age and older. "The FDA's expansion of the emergency use authorization for the Pfizer-BioNTec...
FDA Clears Third COVID-19 Vaccine From Janssen Emergency use authorization for single-dose vaccine that uses unique adenovirus type 26 delivery system for DNA code to reduce severity of coronavirus March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA issued Feb . 27, allows the Janssen Biotech COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and o...